WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

NCT00275314 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
5
Enrollment
OTHER
Sponsor class

Stopped Study never started at our site Funding issue

Conditions

Interventions

Sponsor

University of Pittsburgh

Collaborators